Tau-based therapeutics for Alzheimer's disease: Active and passive immunotherapy

Francesco Panza, Vincenzo Solfrizzi, Davide Seripa, Bruno P. Imbimbo, Madia Lozupone, Andrea Santamato, Rosanna Tortelli, Ilaria Galizia, Camilla Prete, Antonio Daniele, Alberto Pilotto, Antonio Greco, Giancarlo Logroscino

Research output: Contribution to journalReview article

24 Citations (Scopus)

Abstract

Pharmacological manipulation of tau protein in Alzheimer's disease included microtubule-stabilizing agents, tau protein kinase inhibitors, tau aggregation inhibitors, active and passive immunotherapies and, more recently, inhibitors of tau acetylation. Animal studies have shown that both active and passive approaches can remove tau pathology and, in some cases, improve cognitive function. Two active vaccines targeting either nonphosphorylated (AAD-vac1) and phosphorylated tau (ACI-35) have entered Phase I testing. Notwithstanding, the recent discontinuation of the monoclonal antibody RG7345 for Alzheimer's disease, two other antitau antibodies, BMS-986168 and C2N-8E12, are also currently in Phase I testing for progressive supranuclear palsy. After the recent impressive results in animal studies obtained by salsalate, the dimer of salicylic acid, inhibitors of tau acetylation are being actively pursued.

Original languageEnglish
Pages (from-to)1119-1134
Number of pages16
JournalImmunotherapy
Volume8
Issue number9
DOIs
Publication statusPublished - Sep 1 2016

Fingerprint

Active Immunotherapy
Passive Immunization
Acetylation
Alzheimer Disease
Progressive Supranuclear Palsy
tau Proteins
Salicylic Acid
Excipients
Protein Kinase Inhibitors
Microtubules
Cognition
Vaccines
Monoclonal Antibodies
Pharmacology
Pathology
Antibodies
Therapeutics
salicylsalicylic acid
tau-protein kinase

Keywords

  • active immunotherapy
  • Alzheimer's disease
  • passive immunotherapy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Oncology
  • Immunology

Cite this

Panza, F., Solfrizzi, V., Seripa, D., Imbimbo, B. P., Lozupone, M., Santamato, A., ... Logroscino, G. (2016). Tau-based therapeutics for Alzheimer's disease: Active and passive immunotherapy. Immunotherapy, 8(9), 1119-1134. https://doi.org/10.2217/imt-2016-0019

Tau-based therapeutics for Alzheimer's disease : Active and passive immunotherapy. / Panza, Francesco; Solfrizzi, Vincenzo; Seripa, Davide; Imbimbo, Bruno P.; Lozupone, Madia; Santamato, Andrea; Tortelli, Rosanna; Galizia, Ilaria; Prete, Camilla; Daniele, Antonio; Pilotto, Alberto; Greco, Antonio; Logroscino, Giancarlo.

In: Immunotherapy, Vol. 8, No. 9, 01.09.2016, p. 1119-1134.

Research output: Contribution to journalReview article

Panza, F, Solfrizzi, V, Seripa, D, Imbimbo, BP, Lozupone, M, Santamato, A, Tortelli, R, Galizia, I, Prete, C, Daniele, A, Pilotto, A, Greco, A & Logroscino, G 2016, 'Tau-based therapeutics for Alzheimer's disease: Active and passive immunotherapy', Immunotherapy, vol. 8, no. 9, pp. 1119-1134. https://doi.org/10.2217/imt-2016-0019
Panza F, Solfrizzi V, Seripa D, Imbimbo BP, Lozupone M, Santamato A et al. Tau-based therapeutics for Alzheimer's disease: Active and passive immunotherapy. Immunotherapy. 2016 Sep 1;8(9):1119-1134. https://doi.org/10.2217/imt-2016-0019
Panza, Francesco ; Solfrizzi, Vincenzo ; Seripa, Davide ; Imbimbo, Bruno P. ; Lozupone, Madia ; Santamato, Andrea ; Tortelli, Rosanna ; Galizia, Ilaria ; Prete, Camilla ; Daniele, Antonio ; Pilotto, Alberto ; Greco, Antonio ; Logroscino, Giancarlo. / Tau-based therapeutics for Alzheimer's disease : Active and passive immunotherapy. In: Immunotherapy. 2016 ; Vol. 8, No. 9. pp. 1119-1134.
@article{e4817da1926941fdb2433806842fab76,
title = "Tau-based therapeutics for Alzheimer's disease: Active and passive immunotherapy",
abstract = "Pharmacological manipulation of tau protein in Alzheimer's disease included microtubule-stabilizing agents, tau protein kinase inhibitors, tau aggregation inhibitors, active and passive immunotherapies and, more recently, inhibitors of tau acetylation. Animal studies have shown that both active and passive approaches can remove tau pathology and, in some cases, improve cognitive function. Two active vaccines targeting either nonphosphorylated (AAD-vac1) and phosphorylated tau (ACI-35) have entered Phase I testing. Notwithstanding, the recent discontinuation of the monoclonal antibody RG7345 for Alzheimer's disease, two other antitau antibodies, BMS-986168 and C2N-8E12, are also currently in Phase I testing for progressive supranuclear palsy. After the recent impressive results in animal studies obtained by salsalate, the dimer of salicylic acid, inhibitors of tau acetylation are being actively pursued.",
keywords = "active immunotherapy, Alzheimer's disease, passive immunotherapy",
author = "Francesco Panza and Vincenzo Solfrizzi and Davide Seripa and Imbimbo, {Bruno P.} and Madia Lozupone and Andrea Santamato and Rosanna Tortelli and Ilaria Galizia and Camilla Prete and Antonio Daniele and Alberto Pilotto and Antonio Greco and Giancarlo Logroscino",
year = "2016",
month = "9",
day = "1",
doi = "10.2217/imt-2016-0019",
language = "English",
volume = "8",
pages = "1119--1134",
journal = "Immunotherapy",
issn = "1750-743X",
publisher = "Future Medicine Ltd.",
number = "9",

}

TY - JOUR

T1 - Tau-based therapeutics for Alzheimer's disease

T2 - Active and passive immunotherapy

AU - Panza, Francesco

AU - Solfrizzi, Vincenzo

AU - Seripa, Davide

AU - Imbimbo, Bruno P.

AU - Lozupone, Madia

AU - Santamato, Andrea

AU - Tortelli, Rosanna

AU - Galizia, Ilaria

AU - Prete, Camilla

AU - Daniele, Antonio

AU - Pilotto, Alberto

AU - Greco, Antonio

AU - Logroscino, Giancarlo

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Pharmacological manipulation of tau protein in Alzheimer's disease included microtubule-stabilizing agents, tau protein kinase inhibitors, tau aggregation inhibitors, active and passive immunotherapies and, more recently, inhibitors of tau acetylation. Animal studies have shown that both active and passive approaches can remove tau pathology and, in some cases, improve cognitive function. Two active vaccines targeting either nonphosphorylated (AAD-vac1) and phosphorylated tau (ACI-35) have entered Phase I testing. Notwithstanding, the recent discontinuation of the monoclonal antibody RG7345 for Alzheimer's disease, two other antitau antibodies, BMS-986168 and C2N-8E12, are also currently in Phase I testing for progressive supranuclear palsy. After the recent impressive results in animal studies obtained by salsalate, the dimer of salicylic acid, inhibitors of tau acetylation are being actively pursued.

AB - Pharmacological manipulation of tau protein in Alzheimer's disease included microtubule-stabilizing agents, tau protein kinase inhibitors, tau aggregation inhibitors, active and passive immunotherapies and, more recently, inhibitors of tau acetylation. Animal studies have shown that both active and passive approaches can remove tau pathology and, in some cases, improve cognitive function. Two active vaccines targeting either nonphosphorylated (AAD-vac1) and phosphorylated tau (ACI-35) have entered Phase I testing. Notwithstanding, the recent discontinuation of the monoclonal antibody RG7345 for Alzheimer's disease, two other antitau antibodies, BMS-986168 and C2N-8E12, are also currently in Phase I testing for progressive supranuclear palsy. After the recent impressive results in animal studies obtained by salsalate, the dimer of salicylic acid, inhibitors of tau acetylation are being actively pursued.

KW - active immunotherapy

KW - Alzheimer's disease

KW - passive immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=84981263625&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84981263625&partnerID=8YFLogxK

U2 - 10.2217/imt-2016-0019

DO - 10.2217/imt-2016-0019

M3 - Review article

AN - SCOPUS:84981263625

VL - 8

SP - 1119

EP - 1134

JO - Immunotherapy

JF - Immunotherapy

SN - 1750-743X

IS - 9

ER -